STOCK TITAN

Aileron Therapeutics Inc - ALRN STOCK NEWS

Welcome to our dedicated news page for Aileron Therapeutics (Ticker: ALRN), a resource for investors and traders seeking the latest updates and insights on Aileron Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aileron Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aileron Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.28%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.16%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
clinical trial
Aileron Therapeutics Inc

Nasdaq:ALRN

ALRN Rankings

ALRN Stock Data

32.39M
3.73M
0.7%
63.24%
0.67%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About ALRN

aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig